Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009. ,
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012. ,
New perspectives in cancer virotherapy: bringing the immune system into play, Immunotherapy, vol.2, pp.185-99, 2010. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00507434
Non-neoplastic and neoplastic pleural endpoints following fiber exposure, J Toxicol Environ Health B Crit Rev, vol.14, pp.153-78, 2011. ,
Soluble markers for diagnosis of malignant pleural mesothelioma, Biomark Med, vol.5, pp.261-73, 2011. ,
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma, Br J Pharmacol, vol.166, pp.532-53, 2012. ,
What's the place of immunotherapy in malignant mesothelioma treatments?, Cell Adh Migr, vol.4, pp.153-61, 2010. ,
Novel intrapleural therapies for malignant diseases, Respiration, vol.83, pp.277-92, 2012. ,
Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases, Journal of Toxicology and Environmental Health, vol.14, pp.1-67, 2011. ,
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, 2012. ,
, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos (chrysotile, amosite, crocidolite,tremolite, actinolite, and anthophyllite, IARC Monogr Eval Carcinog Risk Chem Man, vol.14, pp.1-106, 2012.
Review on clinical trials of targeted treatments in malignant mesothelioma, Cancer Chemother Pharmacol, vol.68, pp.1-15, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00694874
Mesothelioma not associated with asbestos exposure, Arch Pathol Lab Med, vol.136, pp.262-269, 2012. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
Animal models of malignant mesothelioma, Inhal Toxicol, vol.18, pp.1001-1005, 2006. ,
Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma, Eur J Cancer Prev, vol.21, pp.227-257, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01262920
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids, Lancet, vol.364, pp.1157-66, 2004. ,
Diffuse malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.882-890, 2012. ,
Malignant mesothelioma, Lancet, vol.366, pp.397-408, 2005. ,
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database, J Thorac Oncol, vol.7, pp.1631-1639, 2012. ,
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-95, 2010. ,
Animal models of malignant pleural effusion, Curr Opin Pulm Med, vol.15, pp.343-52, 2009. ,
Surgery for malignant pleural mesothelioma, Expert Rev Respir Med, vol.4, pp.363-72, 2010. ,
Gene therapy for mesothelioma, Curr Treat Options Oncol, vol.12, pp.173-80, 2011. ,
Multimodality strategies in malignant pleural mesothelioma, Semin Thorac Cardiovasc Surg, vol.21, pp.172-178, 2009. ,
Lung carcinoma and malignant mesothelioma in patients exposed to thorotrast : incidence, histology and p53 status, Int J Cancer, vol.63, pp.330-336, 1995. ,
Malignant mesothelioma mortality in the United States, Int J Occup Environ Health, vol.12, pp.9-15, 1999. ,
Factors that impact susceptibility to fiberinduced health effects, J Toxicol Environ Health B Crit Rev, vol.14, pp.246-66, 2011. ,
Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia, Occup Environ Med, vol.61, p.14, 2004. ,
Malignant mesothelioma: global incidence and relationship with asbestos, Ind Health, vol.45, pp.379-87, 2007. ,
Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis, Eur J Epidemiol, vol.16, pp.411-418, 2000. ,
New developments about the association of SV40 with human mesothelioma, Oncogene, vol.22, pp.5173-5180, 2003. ,
Post-irradiation malignant mesothelioma, Cancer, vol.77, pp.1379-1385, 1996. ,
Pleural mesothelioma cases in Biancavilla are related to a new fluoroedenite fibrous amphibole, Arch Environ Health, vol.58, pp.229-261, 2003. ,
Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia, Int J Cancer, 2012. ,
Global mesothelioma deaths reported to the World Health Organization between, Bull World Health Organ, vol.89, pp.724-724, 1994. ,
The French National Mesothelioma Surveillance Program, Occup Environ Med, vol.63, pp.390-395, 2006. ,
Mesothelioma incidence has leveled off in Sweden, Int J Cancer, vol.122, pp.1200-1201, 2008. ,
Non-asbestos related diffuse malignant mesothelioma, Tumori, vol.88, pp.1-9, 2002. ,
, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos (chrysotile, amosite, crocidolite,tremolite, actinolite, and anthophyllite, IARC Monogr Eval Carcinog Risk Chem Man, vol.14, pp.1-106, 2012.
Estimation of the past and future burden of mortality from mesothelioma in France, Occup Environ Med, vol.55, pp.760-765, 1998. ,
Mesothelioma not associated with asbestos exposure, Arch Pathol Lab Med, vol.136, pp.262-269, 2012. ,
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and, Int J Cancer, vol.126, pp.232-238, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00698003
Malignant mesothelioma in Australia, Int J Occup Environ Health, vol.9, pp.206-223, 1945. ,
Modeling mesothelioma risk associated with environmental asbestos exposure, Environ Health Perspect, vol.115, pp.1066-71, 2007. ,
The epidemiology of mesothelioma in historical context, Eur Respir J, vol.9, pp.1932-1974, 1996. ,
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area, Chest, vol.122, pp.2224-2233, 2002. ,
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model, Am J Ind Med, vol.49, pp.1-7, 2006. ,
Mesothelioma mortality in men: trends during 1977-2001 and projections for 2002-2016 in Spain, Occup Environ Med, vol.65, pp.279-82, 2008. ,
Analysis of current trends in United States mesothelioma incidence, Am J Epidemiol, vol.145, pp.211-219, 1997. ,
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through, Am J Epidemiol, vol.159, pp.107-119, 2003. ,
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through, Crit Rev Toxicol, vol.39, pp.576-88, 2005. ,
Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study, Br J Cancer, vol.100, pp.1175-83, 2009. ,
Mesothelioma incidence projections in South East England, Eur Respir J, vol.40, pp.965-973, 2012. ,
Occupations and industries in France at high risk for pleural mesothelioma: A population-based case-control study, Am J Ind Med, vol.53, pp.1207-1226, 1998. ,
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey, Lancet, vol.357, pp.444-449, 2001. ,
Update of predictions of mortality from pleural mesothelioma in the Netherlands, Occup Environ Med, vol.60, pp.50-55, 2003. ,
Projection of mesothelioma mortality in Britain using Bayesian methods, Br J Cancer, vol.103, pp.430-436, 2010. ,
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors, J Natl Cancer Inst, vol.97, pp.1354-65, 2005. ,
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma, Cancer, vol.107, pp.108-123, 2006. ,
The german thorotrast study: recent results and assessment of risks, Radiat Res, vol.152, pp.64-71, 1999. ,
Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-271, 1960. ,
Changing trends in US mesothelioma incidence, Occup Environ Med, vol.62, p.270, 2005. ,
Changing trends in US mesothelioma incidence, Occup Environ Med, vol.61, pp.438-479, 2004. ,
, CLINICAL ASPECTS
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy, ANZ J Surg, vol.79, pp.734-742, 2009. ,
Update on malignant pleural mesothelioma, Semin Respir Crit Care Med, vol.32, pp.102-112, 2011. ,
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients, J Thorac Cardiovasc Surg, vol.135, pp.1-3, 2008. ,
Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011. ,
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis, J Clin Oncol, vol.30, pp.1541-1550, 2012. ,
Molecular biomarkers in malignant mesothelioma: state of the art, Pathology, vol.43, pp.201-213, 2011. ,
Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res, vol.189, pp.169-93, 2011. ,
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour, Thorax, vol.37, pp.810-815, 1982. ,
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice, Lung Cancer, vol.66, pp.150-156, 2009. ,
Thoracoscopy for the diagnosis of pleural disease, Ann Intern Med, vol.114, pp.271-277, 1991. ,
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma, N Engl J Med, vol.367, pp.1417-1444, 2012. ,
Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases, Mayo Clin Proc, vol.60, pp.158-64, 1985. ,
Localised spontaneous regression in mesothelioma --possible immunological mechanism, Lung Cancer, vol.32, pp.197-201, 2001. ,
Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities, Am J Respir Cell Mol Biol, vol.22, pp.550-556, 2000. ,
A proposed new international TNM staging system for malignant pleural mesothelioma, From the International Mesothelioma Interest Group. Chest, vol.108, pp.1122-1130, 1995. ,
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma, Am J Respir Crit Care Med, vol.173, pp.1155-60, 2006. ,
Textbook of Lung Cancer, pp.271-293, 2000. ,
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients, J Thorac Cardiovasc Surg, vol.117, pp.54-63, 1999. ,
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies, J Thorac Cardiovasc Surg, vol.128, pp.138-184, 2004. ,
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies, Eur J Cardiothorac Surg, vol.36, pp.759-63, 2009. ,
, MORPHOLOGICAL CLASSIFICATION
Anti-mesothelial markers in sarcomtoid mesothelioma and other spindle cell neoplasms, Histopathol, vol.37, pp.224-231, 2000. ,
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2, Histopathology, vol.43, pp.231-239, 2003. ,
Diffuse malignant tumors of the serosal membranes, American Registry of Pathology, 2006. ,
The separation of benign and malignant mesothelial proliferations, Am J Surg Pathol, vol.24, pp.1183-200, 2000. ,
The separation of benign and malignant mesothelial proliferations, Arch Pathol Lab Med, vol.136, pp.1217-1243, 2012. ,
Pathology of Malignant Mesothelioma, 2006. ,
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports, Histopathology, vol.49, pp.561-569, 2006. ,
Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res, vol.189, pp.169-93, 2011. ,
, Pathology genetics of tumours of the lung, pleura, thymus and heart, WHO, 2004.
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?, Cancer Treat Rev, 2011. ,
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma, J Mol Diagn, vol.12, pp.771-780, 2010. ,
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011. ,
Second generation sequencing of the mesothelioma tumor genome, PLoS One, vol.5, p.10612, 2010. ,
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am J Respir Cell Mol Biol, vol.42, pp.312-321, 2010. ,
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009. ,
Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma, Cancer Res, vol.70, pp.5686-5694, 2010. ,
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int J Cancer, vol.127, pp.2859-69, 2010. ,
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005. ,
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009. ,
In arrayed ranks: array technology in the study of mesothelioma, J Thorac Oncol, vol.4, pp.411-436, 2009. ,
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009. ,
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004. ,
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma, Am J Pathol, vol.176, pp.881-894, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
2012) microRNAs in cancer management, Lancet Oncol, vol.13, pp.249-58 ,
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases, J Pathol, vol.197, pp.363-71, 2002. ,
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006. ,
Cytogenetic and molecular genetic changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, pp.9-15, 2006. ,
) hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma, Cancer Res, vol.70, pp.1916-1924, 2010. ,
Gene expression profiling in breast cancer: classification, prognostication, and prediction, Lancet, vol.378, pp.1812-1835, 2011. ,
Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis, Am J Pathol, vol.174, pp.762-70, 2009. ,
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation, Pathol Int, vol.61, pp.331-375, 2011. ,
Gene expression profiling of malignant mesothelioma, Clin Cancer Res, vol.9, pp.3080-97, 2003. ,
Transcriptome sequencing of malignant pleural mesothelioma tumors, Proc Natl Acad Sci U S A, vol.105, pp.3521-3527, 2008. ,
Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection, Oncogene, vol.24, pp.1302-1310, 2005. ,
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, pp.181-188, 2009. ,
Aberrant methylation and simian virus 40 Tag sequences in malignant mesothelioma, Cancer Res, vol.61, pp.5727-5730, 2001. ,
Molecular classification of hepatocellular carcinoma, Dig Liver Dis, vol.42, pp.235-276, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00497516
, MESOTHELIOMA THERAPY
Malignant pleural mesothelioma: from the bench to the bedside, Respiration, vol.83, pp.481-93, 2012. ,
Patterns of failure after trimodality therapy for malignant pleural mesothelioma, Ann Thorac Surg, vol.63, pp.334-342, 1997. ,
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed, Thorax, vol.62, pp.690-695, 2007. ,
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium, Lung Cancer, vol.78, pp.76-80, 2012. ,
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma, Int J Cancer, vol.118, pp.521-523, 2006. ,
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma, J Thorac Oncol, vol.3, pp.851-858, 2008. ,
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma, Lung Cancer, vol.77, pp.567-71, 2012. ,
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307, J Thorac Oncol, vol.5, pp.1655-61, 2010. ,
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report, J Thorac Oncol, vol.7, pp.755-764, 2010. ,
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells, Am J Respir Crit Care Med, vol.169, pp.1322-1352, 2004. ,
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors, Cancer Lett, vol.280, pp.125-158, 2009. ,
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma, Lung Cancer, 2010. ,
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, vol.25, pp.2406-2419, 2007. ,
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response, Cancer Res, vol.68, pp.4882-92, 2008. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00330770
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma, Cancer Chemother Pharmacol, vol.61, pp.549-58, 2008. ,
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B, Clin Cancer Res, vol.11, pp.2300-2304, 2005. ,
Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia, Vaccine, vol.21, pp.791-795, 2003. ,
Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma, J Clin Oncol, vol.28, pp.2604-2615, 2010. ,
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment, Clin Cancer Res, vol.13, pp.2928-2963, 2007. ,
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma, J Thorac Cardiovasc Surg, vol.139, pp.1233-1273, 2010. ,
Mesothelin: a new target for immunotherapy, Clin Cancer Res, vol.10, pp.3937-3979, 2004. ,
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.13, pp.5144-5153, 2007. ,
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy, Lung Cancer, vol.68, pp.455-464, 2010. ,
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. American journal of respiratory and critical care medicine, vol.181, pp.1383-90, 2010. ,
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer letters, vol.322, pp.18-34, 2012. ,
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma, Cancer, vol.113, pp.808-822, 2008. ,
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107), Lung Cancer, vol.76, pp.393-399, 2012. ,
Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines, Cancer Lett, vol.278, pp.49-55, 2009. ,
Multicenter, double-blind, placebocontrolled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012. ,
Therapeutic antitumor efficacy of antiepidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma, Int J Oncol, vol.41, pp.1610-1618, 2012. ,
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group, J Thorac Oncol, vol.6, pp.1950-1954, 2011. ,
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma, Eur Respir J, vol.38, pp.1105-1121, 2011. ,
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, pp.83-89, 2005. ,
Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma, Tissue Antigens, vol.74, pp.1-10, 2009. ,
A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma, Lung Cancer, vol.31, pp.67-72, 2001. ,
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer, J Clin Oncol, vol.25, pp.3266-73, 2007. ,
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels, N Engl J Med, vol.353, pp.1564-73, 2005. ,
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma, Lung Cancer, 2006. ,
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies, Clin Cancer Res, vol.13, pp.3605-3615, 2007. ,
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study, Eur Respir J, vol.37, pp.129-164, 2011. ,
A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma, Am J Respir Crit Care Med, vol.184, pp.1395-1404, 2011. ,
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy, Clin Cancer Res, vol.11, pp.7444-53, 2005. ,
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol, vol.12, pp.763-72, 2011. ,
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma, Clin Cancer Res, vol.15, pp.2818-2846, 2009. ,
The MARS feasibility trial: conclusions not supported by data, Lancet Oncol, vol.12, pp.1093-1097, 2011. ,
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma, J Thorac Oncol, vol.5, pp.479-83, 2010. ,
Advances in the biology of malignant pleural mesothelioma, Cancer Treat Rev, vol.37, pp.543-58, 2011. ,
,
Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats, Am J Pathol, vol.129, pp.448-62, 1987. ,
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates, Cell Death and Differentiation, vol.16, pp.1146-1155, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00388174
Establishment of a Murine Model of Malignant Mesothelioma, Intl J Cancer, vol.52, pp.881-886, 1992. ,
Conditional biallelic N?2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2, iMig 2012 meeting Abstract Book, vol.14, pp.1617-1630, 2000. ,
A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-71, 2008. ,
A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent, Cancer Res, vol.66, pp.10786-94, 2006. ,